Phase III Multicentric IIL Study, Three Randomized Arms (R−CVP vs R−CHOP vs R−FM),for Treatment of Patients With Stage II−IV Follicular Lymphoma
Assessment of Overall Survival (OS)in patients treated with R−CVP, R−CHOP and R−FM.
−Assessment of Progression Free Survival (PFS)in patients treated with R−CVP, R−CHOP −
Assessment of Duration of Response (DR)in patients treated with R−CVP, R−CHOP and R−FM. −
Assessment of Response Rate(RR) in patients treated with R−CVP, R−CHOP and R−FM. −
Assessment of molecular Response Rate in patients treated with R−CVP, R−CHOP and R−FM. −
Assessment of toxicity of R−CVP, R−CHOP, R−FM treatments.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Assessment of the Time to Treatment Failure (TTF)in patients treated with R-CVP, R-CHOP and R-FM.
2 years
Yes
Massimo Federico, PhD
Principal Investigator
Azienda Ospedaliera - Universitaria di Modena
Italy: National Monitoring Centre for Clinical Trials - Ministry of Health
IIL−FOLL05
NCT00774826
December 2005
March 2014
Name | Location |
---|